Clinical Significance of CD66b Expression in Non-Small Cell Lung Cancer

We studied the expression of CD66b (a protein of the cancer-embryonic antigen family, expressed mainly in neutrophils) in tumor and stromal cells of non-small cell lung cancer (93 samples). The number of CD66b(+) neutrophils is not associated with clinical and morphological parameters of the tumors and the disease prognosis. However, CD66b is expressed in the tumor cells of most studied samples. CD66b expression is also associated with the histological type of tumor and its localization. Increased expression of CD66b in tumor cells indicated a more favorable prognosis, which allows using this protein as a prognostic marker and as a potential target for the immunotherapy.

Automated summary

We investigated the expression of CD66b in tumor and stromal cells of non-small cell lung cancer samples. The presence of CD66b(+) neutrophils did not correlate with clinical and morphological parameters or prognosis. However, CD66b was expressed in tumor cells of most samples, and its expression correlated with tumor histological type and localization. Increased CD66b expression in tumor cells was associated with a more favorable prognosis, suggesting its potential as a prognostic marker and immunotherapy target.